Hydroxychloroquine for Prevention of Recurrent Miscarriage.

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

December 4, 2017

Primary Completion Date

November 1, 2025

Study Completion Date

February 1, 2026

Conditions
Recurrent MiscarriageFirst Trimester Abortion
Interventions
DRUG

Hydroxychloroquine

Hydroxychloroquine : 200 mg twice a day

DRUG

Placebo

placebo of hydroxychloroquine

Trial Locations (18)

13015

Hôpital Nord - Unité mère-enfant, Marseille

25030

CHU Besançon, Besançon

29000

Centre hospitalier de Cornouaille, Quimper

29609

CHRU de Brest, Brest

32008

CH d'Auch, Auch

35200

Hôpital sud de Rennes, Rennes

40000

CH de Mont de Marsan, Mont-de-Marsan

44093

CHU de Nantes, Nantes

59037

CHRU de Lille, Lille

65013

CH de Bigorre, Tarbes

67091

Nouvel Hôpital Civil, Strasbourg

74374

Centre Hospitalier Annecy Genevois, Annecy

75012

Hopital Saint Antoine, Paris

75018

Hôpital Bichat, Paris

75679

Hopital Port Royal Cochin, Paris

Unknown

CHU Estaing, Clermont-Ferrand

64 000

CHG François Mitterand, Pau

42 270

CHU de Saint Etienne - Hôpital Nord, Saint-Etienne

All Listed Sponsors
lead

University Hospital, Brest

OTHER